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Abstract
Background: HIV case-finding and linkage to care are critical for control of HIV transmission. In Kenya, >50% of
seropositive individuals are unaware of their status. Assisted partner notification is a public health strategy that
provides HIV testing to individuals with sexual exposure to HIV and are at risk of infection and disease. This parallel,
cluster-randomized controlled trial will evaluate the effectiveness, cost-effectiveness, and feasibility of implementing HIV
assisted partner notification services at HIV testing sites (clusters) in Kenya.
Methods/design: Eighteen sites were selected among health facilities in Kenya with well-established, high-volume HIV
testing programs, to reflect diverse communities and health-care settings. Restricted randomization was used to
balance site characteristics between study arms (n = 9 per arm). Sixty individuals testing HIV positive (‘index partners’)
will be enrolled per site (inclusion criteria: ≥18 years, positive HIV test at a study site, willing to disclose sexual partners,
and never enrolled for HIV care; exclusion criteria: pregnancy or high risk of intimate partner violence). Index partners
provide names and contact information for all sexual partners in the past 3 years. At intervention sites, study staff
immediately contact sexual partners to notify them of exposure, offer HIV testing, and link to care if HIV seropositive. At
control sites, passive partner referral is performed according to national guidelines, and assisted partner notification is
delayed by 6 weeks. Primary outcomes, assessed 6 weeks after index partner enrollment and analyzed at the cluster
level, are the number of partners accepting HIV testing and number of HIV infections diagnosed and linked to care per
index partner. Secondary outcomes are the incremental cost-effectiveness of partner notification and the costs of
identifying >1 partner per index case. Participants are closely monitored for adverse outcomes, particularly intimate
partner violence. The study is unblinded due to practical limitations.
Discussion: This rigorously designed trial will inform policy decisions regarding implementation of HIV partner
notification services in Kenya, with possible application to other parts of sub-Saharan Africa. Examination of effectiveness
and cost-effectiveness in diverse settings will enable targeted application and define best practices.
Trial registration: ClinicalTrials.gov NCT01616420.
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Background
HIV testing is central to HIV control. Knowledge of ser-
ostatus promotes safer sexual practices in a variety of
populations [1-4] and is an essential first step in the up-
take of HIV treatment, which improves survival and re-
duces HIV transmission [5]. However, despite increased
awareness of HIV and improved availability of anti-
retroviral therapy (ART), an estimated 60% of infected
individuals in sub-Saharan Africa are unaware of their
status [6].
Assisted partner notification services (APS) is a public
health strategy used to curb the spread of sexually trans-
mitted infections (STIs) by testing and treating the sexual
partners of infected index cases. The intervention typically
involves a public health worker interviewing persons diag-
nosed with an STI (i.e., index cases) about their sexual
partner(s) and then providing the index case with some
level of assistance notifying their partners and assuring
their testing. Some health departments in the US and
Europe developed APS programs for HIV as early as
the 1980s, and APS has been found to increase HIV
case-finding and safer behaviors [7]. Despite its resource-
intensiveness, some studies suggest that APS can be
cost-effective and even cost-saving due to the potential
to prevent HIV transmission and the resulting costs of
HIV care [8]. APS programs incorporate confidentiality
safeguards and intimate partner violence (IPV) screen-
ing, and harms are rarely reported [7]. CDC guidelines
now recommend APS integration into all HIV control
programs [9].
US and European data supporting APS for HIV control
must be cautiously applied to HIV-endemic regions.
Differences in culture, socioeconomic conditions, health
systems, background levels of HIV testing, the status of
youth and women, and perceptions of HIV infection may
all affect the feasibility and effectiveness of APS. Two re-
cent reports from sub-Saharan Africa show promising
results. An HIV APS program in Cameroon diagnosed
one new case of HIV for every 3.2 index cases interviewed
[10]. In a small (n = 245) randomized controlled trial at
STI clinics in Malawi, APS doubled the number of sexual
partners testing for HIV compared to usual practices, and
>50% of these partners were HIV seropositive [11]. In both
reports, APS was acceptable and safe. While these studies
provide preliminary evidence that HIV APS can be pro-
ductively implemented in sub-Saharan Africa, replication
in large, well-designed trials is required before this strategy
is widely adopted.
Kenya has an HIV prevalence of 5.6%. Despite major
national initiatives to improve HIV testing, 53% of HIV-
seropositive individuals are unaware of their status [12],
and most perceive themselves to be at low or no risk
[13]. Currently, there is no HIV APS in Kenya; the
standard of care is passive referral, in which individuals
testing HIV-seropositive are encouraged to disclose their
status to their partners and bring them for testing. HIV
APS has the potential to improve HIV control in Kenya by
identifying those at risk and facilitating both testing and
linkage to care. Kenya’s strong HIV research infrastructure
provides the opportunity to answer relevant questions
about scale-up by rigorously evaluating HIV APS.
These factors brought the Kenyan Ministry of Health’s
National AIDS and STI Control Programme (NASCOP),
Kenyatta National Hospital (KNH), and the University of
Washington together to conduct a cluster-randomized
trial at HIV testing sites in Kenya to evaluate the effective-
ness, cost-effectiveness, and feasibility of HIV APS across
a variety of settings.
The primary objective of the study is to evaluate the
effectiveness of HIV APS in Kenya for HIV case-finding
and linkage to care among sexual partners of index cases.
We hypothesize that APS will increase HIV testing, new
HIV diagnoses, and linkage to care among HIV-positive
partners compared to passive referral, and that case-
finding will be enhanced by extending APS beyond the
primary partner to other sexual partners. We also predict
that HIV APS will be acceptable with minimal social
harms, and that APS will be cost-effective from both payer
and societal perspectives. A cluster-randomized design
was selected to minimize risk of contamination between
arms and to evaluate barriers in implementation and pro-
gram costs at the facility level. Outcomes will be analyzed
at the cluster level. Examining challenges and outcomes
across diverse study sites will provide insights into best
practices to help guide APS implementation.
Methods
Study design
This study is a multicenter, parallel, cluster-randomized
controlled trial. In brief, 18 HIV testing sites in Kenya
(clusters) were selected based on both practical and the-
oretical considerations and allocated to intervention and
control arms (n = 9 clusters per arm) using a restricted
randomization process (details below). In the intervention
arm, APS is implemented immediately after index enroll-
ment; in the control arm, APS is delayed for 6 weeks after
index enrollment. Care provided in the control arm during
the first 6 weeks of randomization is consistent with the
current standard of care in Kenya (i.e., passive referral
with no specialized partner services). Delayed provision of
APS to the control arm allows for evaluation of additional
study outcomes (i.e., partners notified and tested via
APS >6 weeks after study enrollment), as well as providing
these partners the opportunity for HIV testing. Sites enroll
participants in a staggered fashion to ensure adequate
time for individual site preparation and staff training, as
well as oversight of study activities.
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Study sites
Eighteen HIV testing and counselling (HTC) sites in Kenya
were selected as study sites (clusters). HTC in Kenya is
carried out in a variety of settings by counsellors trained
according to NASCOP guidelines [14]. Approaches include
voluntary counselling and testing (VCT), provider-initiated
testing and counselling (PITC), home-based testing, mobile
testing, and antenatal testing. Treatment is provided by
multidisciplinary teams at comprehensive care centers
(CCC). This includes medical evaluation and management;
laboratory monitoring; provision of antiretroviral treatment
(ART) and co-trimoxazole; nutritional, adherence, and
prevention counselling; and psychosocial support ser-
vices [15].
Study sites were selected to reflect the diverse commu-
nities and health-care settings in Kenya in order to in-
crease generalizability of results and to gain insights into
implementing APS in different environments. As the
first step in site selection, NASCOP identified >30 sites
with well-defined VCT and/or PITC programs and mod-
erate to high volume of HIV testing to facilitate timely
completion of the study. Sites were then selected from this
list to ensure diversity in terms of the following: geograph-
ical location within Kenya and by extension sociocultural
practices; proximity to a city (urban, peri-urban, and
rural); HIV prevalence; and health-care facility level. Prin-
cipal investigators and study coordinators conducted site
visits to obtain further details (e.g., the populations served,
existing HTC and CCC services, space, rate of HIV
case-finding). Based on these factors and consent for
participation from facility leadership, they enrolled the
final 18 sites (Figure 1).
Randomization
A restricted randomization process was used for site
(cluster) allocation to intervention and control arms
(Figure 2). To ensure balance between study arms in
terms of key site characteristics, sites were categorized
based on county (Nairobi, Kiambu, Murang’a, Kisumu)
and proximity to a city (urban, peri-urban, rural). Within
each sub-group, all possible randomizations that evenly
distributed the sites into two study arms were generated
using Excel; e.g., there were 70 ways to randomize the
eight urban Nairobi county sites to four sites per arm.
Since there were three peri-urban sites in Kisumu, they
were randomized to two sites to one arm and one site to
the other arm, and the Murang’a site was grouped with
the single Kisumu site. These sub-group randomizations
were then combined in all possible ways to distribute nine
sites into each arm (n = 3,360), and one combination was
selected using a random number generator.
Randomization and allocation were performed at the
University of Washington (USA) by the study statisti-
cian, who had no knowledge of the sites other than the
characteristics used for categorization. Cluster allocation
was not concealed from the sites or study staff. To
minimize bias, randomization was performed after enroll-
ment of all clusters and prior to any individual enrollment.
Table 1 shows the baseline characteristics of the study
sites. Distribution of geographic location and proximity
to urban areas was comparable between study arms as a
result of restricted randomization. Quantitative variables
of interest—total and positive HIV tests per month, gender
of clients, balance between VCT and PITC testing, and
percent of clients testing positive—were similarly distrib-
uted in each study arm, with no significant differences by
Mann–Whitney U test. Unfortunately, data on baseline
rates of linkage to care are not routinely collected. Most of
the selected facilities follow up with clients regarding link-
age to care in some manner (by phone or home visits), and
all have a CCC on site. The KNH VCT site also employs
peer mentors (HIV-positive individuals enrolled in care)
to improve linkage to care for newly diagnosed clients;
no other sites routinely employed peer mentors or other
strategies.
Study procedures
Staff recruitment and training
We recruited NASCOP-certified HTC counselors with re-
search experience to serve as APS study staff, henceforth
referred to as ‘health advisors.’ Staff were trained and sup-
ported to provide high-quality APS by adapting training
materials developed by the Cameroon Baptist Christian
Health Board [10] to the Kenyan setting. Topics included
are as follows: study procedures, client flow, informed
consent processes, participant eligibility, notification of
partners, IPV monitoring, data entry on smartphones,
clinical training on HIV/AIDS staging, treatment and
management, and diagnosis of opportunistic infections
and sexually transmitted infections according to the Kenyan
national guidelines. Refresher training sessions are con-
ducted regularly, including updates on the new HTC al-
gorithm introduced in 2013 by NASCOP [14].
Participants: inclusion/exclusion criteria
Inclusion criteria for index participants are defined as
follows: 1) 18 years or older; 2) able to give informed
consent; 3) HIV-seropositive test result at one of the study
sites; 4) not enrolled in HIV care; and 5) willing to provide
information on at least one sex partner from the preceding
3 years. Exclusion criteria are pregnancy (by self-report)
and/or high risk for IPV due to safety concerns (described
below). Partners are considered eligible for the study if 18
years or older and able to give informed consent.
Index participant enrollment
At study sites, clients are tested and counselled by resident
HTC counsellors according to national HTC guidelines.
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At both intervention and control sites, all clients testing
HIV-seropositive are informed about the APS study by the
HTC counsellors (who are not employed by the study).
If interested, clients are referred to health advisors for
screening. Following a screening informed consent process,
clients are screened for eligibility as an index participant. If
eligible and willing to participate, written consent for
study participation is obtained, and participants are in-
formed whether they are in the immediate or delayed
randomization arm.
Health advisors then administer questionnaires on demo-
graphic characteristics, sexual behavior, HIV testing history,
and HIV care and treatment status. These questionnaires
seek to elicit the following information on each of an index
participant’s sexual partners from the prior 3 years:
home/work addresses and contact information, index
patient’s relationship to the partner (i.e., spouse, girl-
friend or boyfriend, casual contact), and knowledge of the
partner’s HIV status. Index participants are assigned unique
identification numbers, and each partner is assigned a
linked identification number.
Partner notification services
The timeline and components of partner notification in
the intervention arm (immediate APS) and control arm
(delayed APS) are displayed in Figure 3. At sites random-
ized to immediate APS, health advisors encourage index
participants to disclose their HIV status to sexual partners
Figure 1 Distribution of APS study sites in Kenya. The 18 HIV testing and counselling (HTC) sites participating in the APS study are shown on
a map of Kenya, with estimated HIV prevalence among adults for each county [16]. A star (*) indicates that the site was assigned to the intervention
(immediate APS) arm. U, urban; P, peri-urban; R, rural.
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and tell them that they will be contacting their partners
within the next 1–2 weeks, consistent with provider re-
ferral [17]. At sites randomized to delayed APS, health
advisors encourage index participants to disclose their
HIV status to sexual partners (passive referral) as per
HTC guidelines; health advisors then contact partners 6
weeks after index case enrollment.
Partners are first contacted via phone. To enhance cred-
ibility and create a safe space for the ensuing conversation,
health advisors introduce themselves as Ministry of Health
health-care workers based at KNH, the principal National
Referral Hospital in Kenya. If partners ask how their
contact information was obtained, they are told that it
was obtained from a NASCOP database. In the original
protocol, health advisors disclosed that a sexual partner
had provided the contact information, without revealing
the identity of the index participant. However, partners
often declined to participate unless they knew who identi-
fied them. The script was changed after the first month to
facilitate enrollment while protecting the confidentiality
of index participants. This was the only change made to
methods after trial commencement.
Health advisors then inquire whether the partner is
in a suitable environment for health information to be
Figure 2 Restricted cluster randomization of sites in APS study. To ensure balance between study arms for key site characteristics, the 18
sites (clusters) were categorized by county and proximity to an urban area. Randomization was performed for each sub-group, and all possible
combinations of these randomizations were generated. One combination was then selected using a random number generator. Note: the star (*)
indicates that the three Kisumu peri-urban sites were randomized to two in one arm and one in the other; the Murang’a site then occupied the
unfilled spot.
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Table 1 Baseline characteristics of APS study sites based on 2012 data.a
Study arm Study sites County Urban
vs rural
Facility
funding
source
Health
facility
levelb
Number of HTC
staff
Number of
HIV tests
per month
Females
among those
tested (%)
Type of
HTC used
(%)
Number of
positive HIV
tests per month
Positive
among
tested (%)
Females
among
positive
tests (%)
Start date
at site
Intervention:
immediate
APS
Kariobangi
Health Centre
Nairobi Urban Nairobi City
Council
2 2 170 61.1 VCT: 89.8 24 14.2 67.6 October
2013
PITC: 10.2
BabaDogo
VCT Centre
Nairobi Urban Nairobi City
Council
2 2 212 46.4 VCT: 78.8 27 12.9 58.2 April 2014
PITC: 21.2
STC Casino Nairobi Urban Nairobi City
Council
2 1 439 53.1 VCT: 51.1 43 9.9 55.9 July 2014
PITC: 48.9
Mama Lucy Kibaki
Hospital
Nairobi Urban Public 3 2 263 64.7 VCT: 64.1 38 14.3 64.0 July 2014
PITC: 35.9
Karuri Health
Centre
Kiambu Peri-
urban
Public 2 1 287 60.9 VCT: 75.3 13 4.5 61.3 June 2014
PITC: 24.7
JOOTRH-Russia Kisumu Urban Public 3 2 2,262 69.4 VCT: 2.4 134 5.9 68.8 August
2013
PITC: 97.6
Maseno Mission
Hospital
Kisumu Peri-
urban
Private 3 2 79 54.8 VCT: 40.5 6 7.7 58.9 March
2014
PITC: 59.5
Chulaimbo Sub-
District Hospital
Kisumu Peri-
urban
Public 3 3 551 55.2 VCT: 44.4 71 12.9 58.5 June 2014
PITC: 55.6
Ongi’elo Health
Centre
Siaya Rural Public 2 3 199 38.7 VCT: 28.2 15 7.6 59.7 June 2014
PITC: 71.8
Control:
delayed arm
Kenyatta National
Hospital
Nairobi Urban Public 4 7 3,942 60.3 VCT: 26.3 218 5.5 62.3 August
2013
PITC: 73.7
Mbagathi District
Hospital
Nairobi Urban Public 3 9 919 56.5 VCT: 13.4 106 11.6 55.4 November
2013
PITC: 86.6
Huruma Lions
Dispensary (NCC)
Nairobi Urban Nairobi City
Council
2 1 435 76.7 VCT: 72.1 33 7.6 82.1 July 2014
PITC: 27.9
Pumwani Maternity
VCT Centre
Nairobi Urban Nairobi City
Council
3 4 389 64.0 VCT: 100 16 4.1 65.8 July 2014
PITC: 0
Kiambu District
Hospital
Kiambu Peri-
urban
Public 3 2 778 55.0 VCT: 34.1 82 10.5 60.1 November
2013
PITC: 65.9
Kirwara Sub-District
Hospital
Murang’a Peri-
urban
Public 3 1 59 57.0 VCT: 18.3 3 5.0 65.7 June 2014
PITC: 81.7
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Table 1 Baseline characteristics of APS study sites based on 2012 data.a (Continued)
Kisumu District
Hospital
Kisumu Urban Public 3 8 990 60.5 VCT: 23.1 129 13.1 58.9 November
2013
PITC: 76.9
Kombewa
District
Hospital
Kisumu Peri-
urban
Public 3 4 293 52.9 VCT: 55.0 37 12.5 53.5 April 2014
PITC: 45.0
Abidha Health
Centre
Siaya Rural Public 2 2 141 67.4 VCT: 4.5 13 9.1 60.1 May
2014
PITC: 95.5
Abbreviations: APS assisted partner notification services, HTC HIV testing and counselling, NASCOP National AIDS and STI Control Programme, PITC provider-initiated testing and counselling, VCT voluntary testing
and counselling.
aData from the 2012 calendar year provided by the NASCOP Strategic Information Management Unit.
bHealth-care facilities in Kenya are categorized into four levels: 1, community level; 2, sub-district facility; 3, district hospital; and 4, national hospital.
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discussed. If so, health advisors engage in a discussion
about the partner’s health status, especially recent sexual
contacts, risky sexual behavior and possible exposure to
HIV. For individuals who are not in a suitable environ-
ment to discuss their health status, another phone call
is planned or an in-person interview is scheduled.
On the phone or in person, health advisors encourage
HIV testing and describe study objectives and the consent
process. Partners are invited to speak with the health ad-
visor and test for HIV at a study site close to their location.
For those who cannot come to a study site, health advisors
arrange a meeting at a convenient place and time; these
have included partners’ homes, workplaces, or other
public areas. When health advisors meet partners, they
introduce themselves again, producing staff identifica-
tion badges if necessary, and obtain written informed
consent for the study. HTC is then performed. Health
advisors provide HIV testing to those who agree, and
HIV prevention counselling to those who decline. Con-
fidentiality is emphasized throughout the process, and
the partner is assured that their information will not be
shared.
If a partner cannot be reached by phone after four at-
tempts, the health advisor travels to his/her home or work
and discreetly finds a way to speak to the partner in private
so that confidentiality is maintained. They then describe
the study as detailed above. If a partner still cannot be
found after physical tracing, the health advisor verifies the
contact information with the index participant and at-
tempts to trace again. Failed physical tracing (at least three
attempts), partners with insufficient contact information,
and successfully traced partners who decline study partici-
pation are documented. Due to resource constraints, part-
ners residing >50 km from the study site are notified via
phone call, and if they cannot attend a study site for enrol-
ment, they are not enrolled but still strongly encouraged to
test at the nearest HTC facility.
Participant follow-up
Index cases participate in three study visits: one at base-
line for screening/enrolment and two follow-up visits at
6 weeks and 3 months to assess linkage to HIV care, IPV
and other social harms, and risk behaviors.
Partners in the immediate APS arm participate in two
visits: one at baseline for recruitment and a follow-up
visit after 6 weeks to determine whether they have tested
for HIV and linked to care if HIV-seropositive. Linkage
to care is verified by any of the following: CCC registra-
tion number, CD4 count, WHO HIV staging, or com-
mencement of co-trimoxazole and/or ART. Partners in
the delayed APS arm have a single visit scheduled at 6
weeks after enrollment of the index, which serves as a
Figure 3 Study flow for intervention versus control sites, starting from when an index participant tests HIV-seropositive. Illustrated here
are the study procedures for the intervention arm (immediate APS following index participant enrollment) and the control arm (APS delayed for
6 weeks after index participant enrollment). The star (*) indicates that the partner services involve: 1) partner tracing and enrollment; 2) HIV testing and
counselling of partners; and 3) referral of HIV-seropositive partners to HIV care.
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combined recruitment and assessment for any prior
notification, HIV testing, and linkage to care if HIV-
seropositive.
All participants are reminded via phone call on the day
prior to a scheduled visit. Any participants who miss
appointments are traced by health advisors (by phone,
at home, or at work) and rescheduled. Any participants
who cannot be traced at the closure of each study site
(after approximately 6-months duration) are considered
lost to follow-up.
Blinding
This study was carried out in an unblinded fashion. Blind-
ing of study staff and participants was not feasible given
the distinct protocols and timelines of the two study arms,
including procedures for assessment of outcomes.
Data collection: smartphone technology
Quantitative data from both index and partner partici-
pants are collected by health advisors via smartphones
using the Open Data Kit (ODK) platform. Pre-generated
questionnaires programmed using ODK are downloaded
from the NASCOP database and administered to partici-
pants. To optimize data consistency and accuracy at entry,
completed questionnaires are uploaded over an encrypted
connection to the NASCOP server immediately after the
interview. Data verification and analysis are conducted
weekly to ensure rapid, reliable data quality control and
assurance.
Intimate partner violence monitoring
Due to concerns that HIVAPS could lead to IPV for index
cases, safeguards and monitoring for IPV were incorpo-
rated into the study protocol. IPV refers to physical,
sexual, or psychological harm by a current or former
partner or spouse, which can occur among heterosexual
and same-sex couples [18]. We consulted IPV experts and
community organizations regarding how to identify, counsel,
and refer participants with a current or past history of IPV.
Health advisors were trained according to a specific IPV
screening protocol.
During screening, all potential participants are evalu-
ated according to an IPV rating system that classifies
them as low, moderate, or high risk. Individuals at high
risk of IPV (reported IPV within the last 1 month) are not
eligible for the study and are referred to IPV centers for
counselling. We defined individuals at low risk IPV as: 1)
no history of IPV during their lifetime either from a
current or past partner; and 2) no fear of IPV if they par-
ticipate in the study. These participants undergo standard
study procedures and follow-up IPV case reports at 6
weeks and 3 months to capture any interim violence.
Moderate risk IPV individuals were defined to have the
following: 1) a history of IPV during their lifetime either
from a current or past partner; and/or 2) fear of IPV if
they participate in the study. Moderate risk participants
receive additional special monitoring through scheduled
phone calls or home visits at 10, 20, and 30 days after
enrolment, as well as referral to IPV counselling and
treatment centers identified a priori for further evaluation
and management. Reports of IPV during the course of the
study will be assessed on a case-by-case basis by the safety
committee for further guidance. Internal monitoring for
IPV is conducted through weekly data audits and IPV
reports. The study safety committee, with representation
from the study funder, conducts bi-annual meetings to
monitor study progress and any reported IPV.
Outcome measures
Outcomes will be compared between intervention and
control arms based on data collected 6 weeks after en-
rollment of index participants and will be analyzed at
the cluster level.
Primary outcomes are as follows: 1) HIV testing of part-
ners (number of partners of an index participant that were
tested for HIV, offset by the number of partners with loca-
tor information provided by the index participant); 2)
newly identified HIV-infected partners (number of part-
ners of an index participant identified as HIV-infected,
offset by the number of partners of that index participant
who were HIV tested); and 3) linkage to HIV care (number
of partners of an index participant who were linked to HIV
care, offset by the number of partners of an index par-
ticipant identified as HIV-infected; analysis will be limited
to index participants with at least one HIV-infected
partner).
Secondary outcomes are as follows: 1) the incremental
cost per HIV-infected person identified and linked to care,
including ART, and the incremental cost-effectiveness per
incident HIV infection, HIV-related death, and disability
adjusted life-year (DALY) averted in Kenya from payer
and societal perspectives; and 2) costs of identifying >1
partner per index case.
There have been no changes to outcome measures.
Sample size and power analysis
At least 1,080 index participants will be enrolled across
18 HIV testing sites (clusters) with a minimum of 60 index
cases per site. Sample size was calculated to ensure ad-
equate power to address the study’s primary hypothesis:
that immediate APS will increase the number of partners
testing for HIV compared to delayed APS. Calculations
are based on the assumptions that cluster sizes will be
similar and that study sites will be distributed similarly
between arms due to the restricted randomization pro-
cedure, which will increase face validity of the trial and
decrease site-to-site variation across arms. The number
of partners tested for HIV per index case is assumed to
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be Poisson (mean = λ0), and the coefficient of variation
from site-to-site is assumed to be k. We have conserva-
tively estimated k = .25. We also assume that an average
between one and two partners per site will test for HIV
in the delayed arm sites before 6 weeks (−0.2). Finally,
we have assumed that the intervention will increase the
outcome by a minimum factor r = 2 (twofold difference).
Using an adapted Hayes and Moulton formula and conser-
vative estimates (k = 0.25, λ0 = 0.1, α = 0.05 (two-tailed),
with power = 0.80), if 60 participants are enrolled at each
site in each arm, this requires nine sites per arms to see a
twofold difference between the intervention and delayed
arms.
Statistical methods and analysis
For the primary outcomes, generalized estimating equa-
tions models with a Poisson link will be used to compare
intervention and control arms at 6 weeks post-enrollment
of index participants. The use of these models will allow
analysis of data at the cluster level.
Cost-effectiveness analyses will follow the WHO guide-
lines [19] and use mathematical models to simulate the
health outcomes from study data and to consider clinical
outcomes beyond the scope of the study. Using the out-
comes and costs from the study and effectiveness (health
outcomes) estimated by the model, the cost-effectiveness
will be estimated. To estimate effectiveness of APS
compared to existing passive partner notification, a
compartmental, deterministic disease progression and
transmission model for HIV based on previous HIV
and STI models will be used [20]. The model will be
parameterized by data from population-based studies in
Kenya and the literature and validated using Kenyan
demographic health survey and antenatal data. The model
will be used to predict the potential impact of APS on
HIV incidence, progression, and mortality. Sensitivity and
scenario analyses will account for uncertainty in parame-
ters including varying impact of APS on identifying new
HIV cases. Incremental costs for the intervention and
treatment costs incurred (and averted) as a result of the
intervention will be estimated in comparison to existing
passive partner notification and HIV-care costs. Using
these estimates of APS effectiveness and incremental cost
of APS per HIV-positive person identified and treated, the
incremental cost-effectiveness ratio per incident HIV case,
HIV-related death, and DALY averted will be calculated.
Ethics statement
This trial was approved by the Kenyatta National Hospital/
University of Nairobi Ethics Review Committee (P523/10/
2012) and the University of Washington Human Subjects
Institutional Review Board Committee (43628 C). All par-
ticipants in the study provided written informed consent.
The trial is registered at ClinicalTrials.gov (NCT01616420).
Trial status
Implementation of the study began in August 2012. At
the time of submission, the intervention had been intro-
duced to all 18 sites; data collection is ongoing.
Discussion
Provision of partner services in the US and Europe has
been shown to be safe and effective, as well as cost-effective
for HIV case-finding and linkage to care [7,8]. Prior to
launching similar programs in sub-Saharan Africa, it is
important to evaluate HIV APS in rural and urban African
settings, which have different HIV prevalences, affected
populations, sociocultural milieus, and health system
structures and resources. This study is the first cluster-
randomized trial to evaluate HIV APS in sub-Saharan
Africa and builds upon prior work in Cameroon and
Malawi.
In Cameroon, evaluation of an HIV APS program (n =
1,462 indexes) showed that it was feasible to notify part-
ners (60% of named partners), identify new HIV cases
(50% of partners who tested), and link them to care (85%
of those testing positive) [10]. However, APS in Cameroon
was undertaken as a public health program within a large,
faith-based organization providing medical care rather
than a research study. Evaluation of the program was
uncontrolled, did not document the proportion of persons
who accepted the intervention, and did not include
systematic long-term participant follow-up to evaluate
clinical outcomes or adverse events. Thus, while the
Cameroonian experience demonstrates that APS is scal-
able in at least one setting in sub-Saharan Africa and sug-
gests that the intervention is effective, it does not provide
the sort of evidence produced by a randomized trial. A
well-designed individual-level randomized controlled trial
in Malawian STI clinics [11] showed that APS was accept-
able to index cases (89% of those eligible enrolled) and
doubled HIV testing among partners (51% in APS versus
24% in patient referral arm). Sixty-four percent of those
tested were HIV-seropositive, demonstrating that APS
enriches for HIV case-finding, but the applicability of
these results to lower-risk and rural populations is un-
clear. Our study addresses these gaps, and a randomized
design ensures rigorous comparison between intervention
and control arms.
This study is designed to demonstrate whether APS is
more effective than passive referral for identifying indi-
viduals not previously aware of their HIV positive status.
We expect this to be the case based on consistent in-
creases in HIV case-finding associated with APS across
populations and continents [7,10,11]. In African studies,
the rate of HIV-positive cases among partners was greater
than tenfold the national prevalence [6,10,11]. Linkage to
care in the context of APS has been minimally investigated
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[10,21], and this study may contribute important data on
whether APS can link partners to care and treatment.
HIV APS in Kenya also has the potential to be cost ef-
fective. A decision-analysis model based on the Malawian
APS data [22] found that compared to passive referral
APS reduced new transmissions by 12% with an incre-
mental cost-effectiveness ratio (from a health system
perspective) of $4,106 (USD) per transmission averted.
The analysis may have underestimated cost-effectiveness,
since it considered only 1 year of potential transmission
and did not account for payer costs related to opportunis-
tic infections (e.g., hospitalizations). On the other hand,
the analysis may also have overestimated the intervention’s
cost-effectiveness because it assumed that a single health
advisor could work a large number of cases per year,
which probably exceeds what is possible in actual prac-
tice. The cost of APS for each new HIV diagnosis was
higher than that for passive referral ($36 versus $8) but
lower than the cost of HTC strategies in Uganda ($43–231
per new diagnosis) [23]. There are differences between
Malawi and Kenya, including a higher HIV prevalence in
Malawi (10.8% versus 5.6% [24]). Interestingly, at lower
HIV prevalence in the context of poor awareness of HIV
status (as in Kenya), APS may be more cost-effective than
VCT since individuals are less likely to suspect infection
and seek testing [25]. HIV prevalence varies widely within
Kenya, and cost-effectiveness will likely vary under differ-
ent conditions. Combined with data on APS effectiveness
from specific sites, we can identify facilities where introdu-
cing and/or scaling up APS would be most beneficial from
the public health and Ministry of Health perspectives.
In terms of study execution, we have found that health
advisor personalities and training are critical for the suc-
cess of APS. Previous reports have found that individuals
decline HIV APS due to shock and shame about HIV
diagnosis, mistrust of public health services, and fear of
notifying partners [11,26]. APS study health advisors were
selected based on experience as effective HCT counselors
and received additional training on how to build rapport,
assure confidentiality, and convey potential benefits for
index participants and partners. Health advisors report
that index participants often name only one partner but
may reveal additional partners after tactful probing. As
we hypothesize that tracing multiple partners will in-
crease HIV case-finding, health advisors are encouraged
to share non-judgmental approaches to enhance disclos-
ure of multiple partners, while respecting autonomy. Such
approaches would be important to incorporate into an
APS program. We are also planning a qualitative study to
explore why individuals in Kenya may decline to partici-
pate in APS and how such barriers may be overcome.
Challenges have arisen during the partner notification
process. Initially, partners may be resistant to communi-
cation with health advisors due to suspicions about the
identity of the caller (e.g., prank caller, debt collectors).
These concerns are usually assuaged by producing proof
of identification and affiliation with the Ministry of
Health-NASCOP and KNH. As described, the script for
partner notification was modified early in the study to
avoid partners demanding to know who provided their
information; this has improved acceptance. Another
challenge for health advisors is verbal abuse from part-
ners during phone calls. Though they have never en-
countered physical violence, staff are expected to follow
safety precautions such as travelling in pairs to risky or
remote areas. Finally, enrollment of notified partners has
been difficult at some sites. Success likely depends on the
approach of health advisors, partner populations, and the
interaction between them. Exploring how effectiveness
varies by site characteristics and health advisor may high-
light best practices.
We have also encountered health system challenges dur-
ing the study. Kenya experiences shortages of HIV diag-
nostic test kits, and this has impeded enrollment at some
sites more than others. At some facilities, CD4 testing was
temporarily unavailable due to flow cytometer breakdown,
hindering fulfillment of linkage-to-care criteria. While
these resource limitations are reflective of the reality on
the ground, they may skew measurement of intervention
effectiveness given the 6-week time constraint for partner
tracing and linkage to care and depending on which sites
in each study arm are affected. They may also inflate the
calculated costs of APS by prolonging the time required
for enrollment, tracing, and testing. We have attempted to
minimize such effects by sharing test kits between sites,
ordering kits directly from suppliers when necessary, and
shipping samples to other laboratories for CD4 testing.
Our analyses will require interpretation in light of these
systemic issues.
Active monitoring for IPV among index cases is on-
going, given the close association between HIV and IPV
[27,28]. Baseline screening has identified both women
and men experiencing IPV, and these cases were handled
as per protocol. Similar to published literature [7,10,11],
we have not detected any new or worsening IPV due to
APS. Occasionally, APS has caused other social harms,
such as relationship dissolution. Developing strategies to
support individuals will be necessary if APS is scaled-up.
Study limitations
There may be limitations to this study in terms of repre-
sentativeness. We selected study sites to reflect the geo-
graphic, socioeconomic, and cultural diversity in Kenya.
However, practical factors such as space constraints or
testing volumes excluded certain facilities.
At the index participant level, certain groups may be
underrepresented, as those reluctant to participate may
decline referral to health advisors. For example, individuals
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facing stigma related to their partners—e.g., men having
sex with men, commercial sex workers—may be less likely
to participate for fear of discrimination. We attempted to
mitigate this via staff sensitivity training and by including
a site that primarily serves sex workers; however, a differ-
ent study design would be required to fully address this
question in key affected populations. Individuals hospital-
ized with advanced HIV disease and diagnosed through
PITC may be excluded due to inability to consent, even
though their partners are highly likely to benefit from APS.
At the partner participant level, some partners who were
meant to be followed up after 6 weeks were instead
brought in by the index partner immediately for notifica-
tion, making it difficult to maintain site integrity. More-
over, it is difficult to trace partners who are homeless, lack
reliable phone access or contact information, or reside in
inaccessible regions. We excluded partners >50 km away
from the study site due to resource constraints, though a
nationwide program could overcome this through a health
advisor network. The other issues will require solutions
that balance cost-effectiveness with equity for vulnerable
populations.
Some aspects of our study may be difficult to translate
to a program level. The use of smartphones for data in-
put and transmission to a central database has increased
efficiency and portability and likely avoided transcription
errors. However, these devices are relatively expensive
and in the absence of widespread electronic medical re-
cords in Kenya, it is unclear how feasible and cost-effective
this would be for scale-up of HIV APS. They may be more
cost-effective in the long run compared to computers that
require a power source and security measures. Finally,
while blinding was not feasible with this study design, and
most outcomes are objective, lack of blinding could
contribute to biases, such as how intensely health advi-
sors pursue tracing or encourage HIV testing.
Conclusions
In summary, this large cluster-randomized trial will pro-
vide critical data on the effectiveness, cost-effectiveness,
and feasibility of HIV APS in sub-Saharan Africa and fa-
cilitate rational, targeted application of APS in Kenya
and potentially diverse environments in Africa. Trial im-
plementation would not be feasible without the long-
standing collaboration between KNH, NASCOP, and
University of Washington, all organizations with strong
commitments to investigate the utility of APS as part
of Kenya’s HIV control strategy. HIV APS experts in
Cameroon and the US also provided invaluable guidance
regarding study design, health advisor training, program
implementation, and IPV monitoring. Kenyan health offi-
cials and academics will continue to collaborate in order
to apply study results within the health system. Our inves-
tigation may uncover concerns unique to the Kenyan
setting and will inform programmatic implementation of
HIVAPS if this trial demonstrates effectiveness.
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